Lakefront Biotherapeutics NV (XTER:GXE) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:GXE Lakefront Biotherapeutics NV XTER:GXE
58 GF Score
Price €22.88
GF Value €110.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XTER:GXE
58GF Score
Lakefront Biotherapeutics NV XTER:GXE
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lakefront Biotherapeutics NV (XTER:GXE) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of €22.88 is trading 79.2% below its estimated GF Value™ of €110.02. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for XTER:GXE:

  • Dividends Received:
  • GF Value™: €110.02 vs. price of €22.88 (79.2% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the XTER:GXE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
58GF Score

Get the complete analysis for XTER:GXE

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.88
Price
€110.02
GF Value